| Ytd | -63.76% | |
| 1y | -88.88% |
| Open | 0.24 | Prev Close | 0.25 | Low | 0.24 | High | 0.25 | Mkt Cap | 323.05K |
| Vol | 76.73K | Avg Vol | 3.71M | EPS | -14.23 | P/E | -0.02 | Forward P/E | N/A |
| Beta | 2.11 | Short Ratio | 0.09 | Inst. Own | 2.36% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.37 | 200-d Avg | 0.77 | 1yr Est | 700.00 |
Gainers Catheter Precision (AMEX:VTAK) shares rose 78.2% to $1.55 during Monday's after-market
JERUSALEM, June 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or
JERUSALEM, May 20, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or t
JERUSALEM, May 15, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or
Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the compan
Scinai Immunotherapeutics Ltd – ADR (NASDAQ:SCNI) shares are surging Friday morning after the compan
Financing led by institutional life sciences investor, with participation from new and existing inve
TopBuild Corp (NYSE: BLD) rises in pre-market trading after QXO (NYSE: QXO) agrees to acquire for $1
JERUSALEM, April 6, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai"
JERUSALEM, April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" o
JERUSALEM, March 19, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharma
JERUSALEM, March 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai"
Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ: SCNI - Get Free Report) was the recipient of a
JERUSALEM, March 2, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai" o
JERUSALEM, Feb. 25, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai", or
JERUSALEM, Feb. 17, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd . (NASDAQ: SCNI) ("Scinai", o
JERUSALEM, Jan. 7, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI); ("Scinai", or
Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ: SCNI - Get Free Report) was the target of a la
Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ: SCNI - Get Free Report)'s share price shot up
JERUSALEM , Dec. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or
Grant funds two-thirds of a NIS 1.23 million ($373K) project to strengthen Scinai Bioservices' small
JERUSALEM , Sept. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.
New data builds on award-winning research and confirms efficacy and safety of PC111 across in-vitro,
On Wednesday, 311 stocks hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.